<p>/PRNewswire/ -- 一项重要的新临床研究 SUPER 2 已在《自然通讯》上发表，报告称长效 GLP-1 受体激动剂 Efsubaglutide Alfa 显著改善了在美托洛尔控制不佳的 2 型糖尿病成人的血糖控制，同时还显示出有利的β细胞功能反应。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>该研究由中国科学院院士贾伟平领导，复旦大学特聘教授、Innogen Pharmaceuticals 创始人及 Efsubaglutide Alfa 的发明人王青华教授共同通讯。该出版物标志着 Efsubaglutide Alfa 临床开发的又一个重要里程碑，并进一步提供了其治疗价值超越降糖的机制性见解。</p>
<p>SUPER 2 是一项随机、双盲、安慰剂对照的两阶段自适应 IIb/III 期试验，评估 Efsubaglutide Alfa 作为美托洛尔的附加治疗在 2 型糖尿病患者中的效果。结果显示，Efsubaglutide Alfa 显著改善了 HbA1c 和其他关键的血糖指标，其整体安全性特征与 GLP-1 受体激动剂类别一致，主要为轻至中度的胃肠道不良事件。</p>
<p>重要的是，该研究超越了传统的疗效终点，进一步通过混合餐耐受测试和相关代谢指标考察了β细胞功能反应。Efsubaglutide Alfa 的治疗与餐后胰岛素和 C 肽反应的改善、β细胞功能相关参数的改善以及反映胰岛素分泌与胰岛素敏感性之间综合关系的指标的有利变化相关。这些发现表明，Efsubaglutide Alfa 的临床益处可能超越血糖控制，部分改善 2 型糖尿病的潜在病理生理。</p>
<p>这一机制信号在团队早期的糖尿病缓解研究的背景下尤为重要，该研究发表在《治疗进展》上，显示 Efsubaglutide Alfa 在未用药的 2 型糖尿病患者中治疗后撤药与部分患者的缓解相关。SUPER 2 的数据现在为β细胞功能的改善可能有助于 Efsubaglutide Alfa 长期疾病修饰潜力的概念提供了更大规模的临床支持。</p>
<p>Innogen Pharmaceuticals 是一家以创新为驱动的生物制药公司，专注于糖尿病和其他代谢疾病的新疗法的发现、开发和转化。《自然通讯》上 SUPER 2 的发表不仅加强了 Efsubaglutide Alfa 的临床证据基础，还突显了整合机制科学、临床开发和转化医学以推进代谢疾病下一代疗法的价值。</p>
<p>来源：Innogen Pharmaceuticals</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEyJk5ld3NJdGVtSWQ9Q041ODM2NSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTIyMzQ2UFJfTkVXU19VU1BSX19fX19DTjU4MzY1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEyJk5ld3NJdGVtSWQ9Q041ODM2NSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTIyMzQ2UFJfTkVXU19VU1BSX19fX19DTjU4MzY1"/></p>

生物科技 ETF - VanEck Vectors

招商中证生物科技主题ETF

华宝恒生港股通创新药精选ETF

<p>一项发表在《自然通讯》上的新临床研究强调了 Efsubaglutide Alfa（一种 GLP-1 受体激动剂）对控制血糖和β细胞功能的影响，研究对象为在二甲双胍治疗下控制不佳的 2 型糖尿病成人。SUPER 2 试验显示 HbA1c 及其他血糖指标有显著改善，安全性特征与 GLP-1 类药物一致。研究结果表明，Efsubaglutide Alfa 可能还改善β细胞功能，暗示其在血糖控制之外可能具有长期益处。Innogen Pharmaceuticals 主导了该研究，强调了在开发代谢疾病治疗方案中机制性见解的重要性</p>

<p>, /PRNewswire/ -- A major new clinical study, SUPER 2, has been published in <em>Nature Communications</em>, reporting that Efsubaglutide Alfa, a long-acting GLP-1 receptor agonist, significantly improved glycaemic control in adults with type 2 diabetes inadequately controlled on metformin, while also demonstrating favorable β-cell functional responses.</p>
<div class="lb-trans"><p>/PRNewswire/ -- 一项重要的新临床研究 SUPER 2 已在《自然通讯》上发表，报告称长效 GLP-1 受体激动剂 Efsubaglutide Alfa 显著改善了在美托洛尔控制不佳的 2 型糖尿病成人的血糖控制，同时还显示出有利的β细胞功能反应。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>The study was led by Academician Weiping Jia and co-corresponded by Professor Qinghua Wang, Distinguished Professor of Fudan University, Founder of Innogen Pharmaceuticals, and inventor of Efsubaglutide Alfa. The publication marks another important milestone in the clinical development of Efsubaglutide Alfa and provides further mechanistic insights into its therapeutic value beyond glucose lowering.</p>
<div class="lb-trans"><p>该研究由中国科学院院士贾伟平领导，复旦大学特聘教授、Innogen Pharmaceuticals 创始人及 Efsubaglutide Alfa 的发明人王青华教授共同通讯。该出版物标志着 Efsubaglutide Alfa 临床开发的又一个重要里程碑，并进一步提供了其治疗价值超越降糖的机制性见解。</p>
</div><p>SUPER 2 was a randomized, double-blind, placebo-controlled, two-stage adaptive phase IIb/III trial evaluating Efsubaglutide Alfa as add-on therapy to metformin in patients with type 2 diabetes. The results showed that Efsubaglutide Alfa significantly improved HbA1c and other key glycaemic measures, with an overall safety profile consistent with the GLP-1 receptor agonist class, with mainly mild-to-moderate gastrointestinal adverse events.</p>
<div class="lb-trans"><p>SUPER 2 是一项随机、双盲、安慰剂对照的两阶段自适应 IIb/III 期试验，评估 Efsubaglutide Alfa 作为美托洛尔的附加治疗在 2 型糖尿病患者中的效果。结果显示，Efsubaglutide Alfa 显著改善了 HbA1c 和其他关键的血糖指标，其整体安全性特征与 GLP-1 受体激动剂类别一致，主要为轻至中度的胃肠道不良事件。</p>
</div><p>Importantly, the study went beyond conventional efficacy endpoints and further examined β-cell functional responses using mixed-meal tolerance testing and related metabolic indices. Treatment with Efsubaglutide Alfa was associated with improved postprandial insulin and C-peptide responses, improvement in β-cell function-related parameters, and favorable changes in indices reflecting the integrated relationship between insulin secretion and insulin sensitivity. These findings suggest that the clinical benefit of Efsubaglutide Alfa may extend beyond glycaemic control to partial improvement of the underlying pathophysiology of type 2 diabetes.</p>
<div class="lb-trans"><p>重要的是，该研究超越了传统的疗效终点，进一步通过混合餐耐受测试和相关代谢指标考察了β细胞功能反应。Efsubaglutide Alfa 的治疗与餐后胰岛素和 C 肽反应的改善、β细胞功能相关参数的改善以及反映胰岛素分泌与胰岛素敏感性之间综合关系的指标的有利变化相关。这些发现表明，Efsubaglutide Alfa 的临床益处可能超越血糖控制，部分改善 2 型糖尿病的潜在病理生理。</p>
</div><p>This mechanistic signal is particularly meaningful in light of the team's earlier Diabetes Remission study, published in <em>Advances in Therapy</em>, which showed that Efsubaglutide Alfa treatment in drug-naïve patients with type 2 diabetes was associated with remission in a proportion of patients after treatment withdrawal. The SUPER 2 data now provide larger-scale clinical support for the concept that improvement in β-cell function may contribute to the longer-term disease-modifying potential of Efsubaglutide Alfa.</p>
<div class="lb-trans"><p>这一机制信号在团队早期的糖尿病缓解研究的背景下尤为重要，该研究发表在《治疗进展》上，显示 Efsubaglutide Alfa 在未用药的 2 型糖尿病患者中治疗后撤药与部分患者的缓解相关。SUPER 2 的数据现在为β细胞功能的改善可能有助于 Efsubaglutide Alfa 长期疾病修饰潜力的概念提供了更大规模的临床支持。</p>
</div><p>Innogen Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the discovery, development, and translation of novel therapies for diabetes and other metabolic diseases. The publication of SUPER 2 in <em>Nature Communications</em> not only strengthens the clinical evidence base for Efsubaglutide Alfa, but also highlights the value of integrating mechanistic science, clinical development, and translational medicine to advance next-generation therapies for metabolic diseases.</p>
<div class="lb-trans"><p>Innogen Pharmaceuticals 是一家以创新为驱动的生物制药公司，专注于糖尿病和其他代谢疾病的新疗法的发现、开发和转化。《自然通讯》上 SUPER 2 的发表不仅加强了 Efsubaglutide Alfa 的临床证据基础，还突显了整合机制科学、临床开发和转化医学以推进代谢疾病下一代疗法的价值。</p>
</div><p>SOURCE Innogen Pharmaceuticals</p>
<div class="lb-trans"><p>来源：Innogen Pharmaceuticals</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEyJk5ld3NJdGVtSWQ9Q041ODM2NSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTIyMzQ2UFJfTkVXU19VU1BSX19fX19DTjU4MzY1" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN58365&amp;Transmission_Id=202605122346PR_NEWS_USPR_____CN58365&amp;DateId=20260512"/></p>

23:47 ETNew Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function

prnewswire

标普生物技术 ETF - SPDR

科创医药ETF工银

香港医药

国泰中证生物医药ETF

易方达沪深300医药ETF

广发中证香港创新药(QDII-ETF)

生物科技ETF基金

2 倍做空纳斯达克生物技术 ETF - ProShares

医疗业 ETF - Vanguard

天弘国证生物医药ETF

方正富邦中证医药及医疗器械创新ETF

纽交所高增长板生物技术指数 ETF - First Trust

美国制药 ETF - iShares

BlackRock, Inc.

华夏医药ETF

华夏恒生生物科技ETF(QDII)

华夏中证生物科技主题ETF

医药突破 ETF - ALPS

华安恒生生物科技ETF

博时恒生港股通创新药精选ETF

易方达恒生港股通创新药ETF

标普全球医疗股指数 ETF - iShares

华夏上证科创板生物医药ETF

富国恒生港股通创新药及医疗保健ETF

标普生物技术 3 倍做多 - Direxion

2 倍做多纳斯达克生物技术 ETF - ProShares

鹏华上证科创板生物医药ETF

平安中证医疗创新ETF

易方达中证生物科技主题ETF

动态生物技术与基因组 ETF - Invesco

南方恒生生物科技ETF(QDII)

纳斯达克生物科技指数 ETF - iShares Nasdaq

博时恒生医疗保健(QDII-ETF)

基因改革 ETF - ARK

创新药

医疗业 ETF - SPDR

银诺医药-B

23:47 ET 新的《自然通讯》刊物重点介绍了 Efsubaglutide Alfa 对血糖水平和β细胞功能的影响